About Us - Carthera(4) Michael Canney, Ph.D. | LinkedIn

In this episode, Curtis Vallier speaks with Dr. MichaelCanney, Chief Scientific Officer at Carthera, about innovative treatments forbrain cancer, particularly glioblastoma. They discuss the challenges posed bythe blood-brain barrier and how ultrasound technology can temporarily disruptit to enhance drug delivery. The conversation also covers the ongoing clinicaltrials, the unmet needs in glioblastoma treatment, and the potential for thistechnology to expand to other types of brain cancer. Dr. Canney emphasizes theimportance of collaboration in research and expresses optimism for futureadvancements in cancer therapies.